Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Nemirovsky

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer|March 23, 2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesBeryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, et al.
Blood Advances|April 8, 2025
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy InductionMeira Yisraeli Salman, Alexander R Terry, Andriy Derkach, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Cancer|August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costsHannah Burton, Leora Boussi, David Nemirovsky, et al.
Cancer Discovery|August 31, 2023
Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic ImplicationsBritta Weigelt, Antonio Marra, Pier Selenica, et al.
Transplantation and Cellular Therapy|December 19, 2024
Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care InterventionAbigail G Cohen, Christina Cho, Emily Patterson, et al.
Transplantation and Cellular Therapy|October 8, 2023
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell TherapyMaria-Stefania Infante, David Nemirovsky, Sean Devlin, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer|March 23, 2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapiesBeryl L Manning-Geist, Ryan M Kahn, David Nemirovsky, et al.
Blood Advances|April 8, 2025
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Initial Response to Intensive Chemotherapy InductionMeira Yisraeli Salman, Alexander R Terry, Andriy Derkach, et al.
Research Square|March 3, 2023
Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple MyelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Cancer|August 7, 2025
Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costsHannah Burton, Leora Boussi, David Nemirovsky, et al.
Cancer Discovery|August 31, 2023
Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic ImplicationsBritta Weigelt, Antonio Marra, Pier Selenica, et al.
Transplantation and Cellular Therapy|December 19, 2024
Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care InterventionAbigail G Cohen, Christina Cho, Emily Patterson, et al.
Transplantation and Cellular Therapy|October 8, 2023
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell TherapyMaria-Stefania Infante, David Nemirovsky, Sean Devlin, et al.
Blood Cancer Journal|July 25, 2023
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myelomaCarlyn Rose Tan, Andriy Derkach, David Nemirovsky, et al.
Research Square|February 26, 2024
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple MyelomaAlexander Lesokhin, Karthik Nath, Tala Shekarkhand, et al.
Blood Neoplasia|June 27, 2025
Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: a real-world experienceMalin Hultcrantz, Andriy Derkach, Hani Hassoun, et al.
Pageof 4